Coagulation disorders are a common complication in patients with chronic kidney disease (CKD), with thrombosis being the most common cause of death [1] . Recently Huang et al. [2] found that patients with CKD are characterized by increased factor VIII (FVIII) activity and endothelial dysfunction, as apparent from increased von Willebrand factor (VWF) antigen levels.
VWF exerts a procoagulant effect by carrying FVIII and mediating platelet adhesion and aggregation. Under physiological conditions, VWF adopts a globular conformation and is unable to interact spontaneously with platelets. Pathologically, high shear or binding to exposed subendothelial collagen at sites of vascular injury can result in unfolding, thereby exposing the VWF A1 domain [3] . This active conformation allows binding of VWF to the platelet glycoprotein Ib-IX-V receptor complex [4] . Additionally, ultralarge (UL)-VWF multimers are released from endothelial cells upon activation. These UL-VWF multimers are in their active, platelet-binding conformation, but are normally cleaved immediately by a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) [4] .
Circulating active VWF is increased in various patient populations suffering from thrombotic complications [5] . Therefore we assessed if levels of active VWF are also affected by various stages of kidney disease.
Using an enzyme-linked immunosorbent assay [6] , we determined active VWF levels in plasma from a cohort of patients (55% male) with renal disease. The cohort comprised patients not receiving haemodialysis [CKD, n ¼ 25, mean age 61 6 13 years, body mass index (BMI) 29. 3 (Figure 1B) , corroborating previous reports [2, 7] , but did not show the same trend with increased disease severity.
The underlying pathophysiological mechanism is likely related to chronic exposure of endothelium to inflammatory cytokines and oxidative stress [8] . As a result, with progressing stages of kidney disease, ongoing damage and/or activation of the endothelium lead to the release of increasingly large amounts of UL-VWF into the circulation. The degree of endothelial activation may also be related to the dialysis modality, as a trend towards higher active VWF levels in PD-ESRD compared with HD-ESRD patients can be observed. Additionally, a previous study [9] found substantially decreased ADAMTS13 levels in CKD patients compared with controls. This reduction in ADAMTS13 levels may be caused by increased loss via urine due to damage to the glomerular filtration membrane. Consequently, a proportion of UL-VWF will not be proteolysed, but remains in its active conformation. Interestingly, we observed a significant correlation (Spearman r ¼ 0.390, P ¼ 0.0021) between urinary protein (including ADAMTS13) loss (measured as ACR) and circulating active VWF levels in our study population.
In summary, circulating levels of total VWF and, even more pronounced, active VWF are increased in patients with CKD and ESRD compared with healthy controls. High plasma VWF levels were previously found to be a predictor of microalbuminuria, CVD and mortality in both diabetic and non-diabetic patients [10] . We hypothesize that active VWF, being the haemostatically active fraction of VWF, may be even more strongly associated with cardiovascular morbidity and mortality. However, followup studies with larger patient numbers are required to determine the mechanism behind increased active VWF in CKD, by examining the association between active VWF, circulating and urinary ADAMTS13 levels and the presence of an arteriovenous fistula. In addition, clinical follow-up data are required to unravel the relationship of active VWF and clinical outcome.
